Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 10« First...34567...10...Last »

WikiLeaks: Clinton Emails Expose Biopharma Chatter

The ninth batch of presidential candidate Hillary Clinton’s emails released by WikiLeaks has some biopharma gossip that includes Clinton’s team discussing the FDA’s commissioner and it’s so-called “war on pharma.”

Read More »

Pfizer Expansion Has $2.2 Billion Economic Impact, Could Mean 5,680 Jobs in Michigan

A study found that Pfizer’s Michigan manufacturing facility impacts Kalamazoo and Van Buren counties to the tune of about $2.2 billion.

Read More »

How One Tweet From Bernie Sanders Sent Ariad’s Stock Plunging

One tweet. That is all it took from U.S. Senator Bernie Sanders to cause shares of Ariad Pharmaceuticals to drop 15 percent.

Read More »

Top 50 Companies: Notes & Methodology

For this annual special report, which is in its 30th year of publication, Med Ad News editors rank and profile the world’s top 50 companies that generate revenue from healthcare products.

Read More »

2016 Annual Report: Top 50 Companies – Pipelines & Pricing

The amount of new drug approvals in 2015 was the FDA’s highest total since 1950 due in part to revamped pipelines, but a tough future looms as the grumblings over pricing have risen to a roar.

Read More »

Cash works, but activity trackers may do little to boost exercise

Health might be its own reward, but even cash incentives only work in the short term to motivate people to exercise more and activity trackers add little benefit, according to a study from Singapore.

Read More »

Scientists seek to map all human cells in vast atlas

Scientists launched a global initiative to map out and describe every cell in the human body in a vast atlas that could transform research.

Read More »

EMA panel conditionally approves leukemia drug

AbbVie Inc. won the conditional backing of an advisory committee of the European Medicines Agency (EMA) for a drug to treat a form of blood cancer.

Read More »

Intercept’s liver drug gets conditional backing of EMA panel

Drugmaker Intercept Pharmaceuticals Inc.’s drug to treat a rare liver condition was conditionally approved an advisory committee to the European Medicines Agency.

Read More »

Tesaro Attempts to Squash Partner Myriad Genetics’ Contrary Press Release Over Niraparib

Riding high off of positive Phase III data for its PARP inhibitor niraparib, Tesaro Inc. is not looking for anyone to burst its bubble, including Myriad Genetics, which developed the companion diagnostic test Tesaro used in the Phase III trial.

Read More »

TG Therapeutics Stock Plunges as Company Modifies Phase III Cancer Trial Protocols

TG Therapeutics stock took a dive on news that it was modifying the protocols in its Phase III clinical trial of TG-1101 for relapsed/refractory high-risk chronic lymphocytic leukemia (CLL).

Read More »

AbbVie: Welcome Back

Just a few years after its spin-off from Abbott, Med Ad News Company of the Year AbbVie is very much back in the big pharma conversation.

Read More »

Amgen: Transforming For The Future

Amgen has focused the company’s business and operating model through significant transformation and process improvement efforts to produce innovative medicines while generating satisfactory investor returns.

Read More »

AstraZeneca: Expecting A Rich Harvest

AstraZeneca continues to rely on its growth platforms to bring the company back on track, weathering patent expirations as it cultivates the pipeline with many promising products.

Read More »

U.S. breast cancer deaths drop; rate among white women falls most

U.S. death rates from breast cancer have dropped, although the decline was still greater among white women than black women, according to a study.

Read More »

UK to ‘fast track’ most cost-effective new drugs

Britain’s healthcare cost agency NICE plans to fast-track its recommendations for the most cost-effective new drugs.

Read More »

Denmark’s Genmab looks to immunotherapy for cancer drug encore

Immunotherapy, which boosts the immune system to fight cancer, could be the next big opportunity for Genmab, potentially driving peak sales of its top-selling drug well past $10 billion a year, its chief executive believes.

Read More »

Efforts to beat tuberculosis fall far short, WHO warns

Health authorities worldwide need to move much faster to prevent, detect and treat a “deadly epidemic” of tuberculosis if they are to reduce TB infections and deaths by 2030, the World Health Organization warned.

Read More »

Pfizer loses appeal in UK patent case over use of Lyrica drug for pain

Pfizer suffered a setback in Britain when the Court of Appeal in London ruled against it in a patent case over the use of its $5 billion-a-year drug Lyrica for pain relief.

Read More »

Google’s Verily to Tackle Zika

Verily, Google’s life sciences division, aims to eliminate the threat of the mosquito-borne Zika virus by figuring out how to prevent the pesky pests from reproducing.

Read More »

Page 5 of 10« First...34567...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom